Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Year: 2018
Type: article
Study design: Clinical Trial
Authors: Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E. Krop, Howard Burris, Angel Guerrero-Zotano, Carolyn D. Britten, Carlos Becerra, Jan Schellens, Donald A. Richards, Martin Schuler, Maysa Abu-Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, Jose Baselga
Institutions: Vall d'Hebron Hospital Universitari, INCLIVA Health Research Institute, Dana-Farber Cancer Institute, Sarah Cannon, Fundación Instituto Valenciano de Oncología, Medical University of South Carolina, Texas Oncology, The Netherlands Cancer Institute, Essen University Hospital, Thomas Jefferson University, The University of Texas MD Anderson Cancer Center, University of Manchester, Greenville Memorial Hospital, Novartis (Switzerland), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Award: Cancer Center Support Grant
OpenAlex ID: W2805565785